ClinicalTrials.gg
RecruitingNCT06076005LUNG-CANCERUpdated Oct 27, 2026

Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor

An observational study in Lung Cancer Stage IV, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Lung Neoplasms with a site in Italy — 87 open to participants now, 116 under way, 24 of them phase 3. Lung Neoplasms · Italy.

Planned enrollment
19th of 91
1,000 · median 200
Started
2023
with 21 others
Observational
91 of 300
39 open now
Primary completion
2026-10
later than 44 of 115 live
Registered
218th of 300
by date
Lead sponsor
7 of 300
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 300 studies in Lung Neoplasms with a site in Italy, this one is the 19th largest by planned enrollment of the 91 observational ones that give a count, is one of 22 that started in 2023, is one of 91 observational ones, reaches primary completion later than 44 of the 115 other live ones, and was the 218th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

87 of the 300 studies in Lung Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Lung Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.

03

Conditions studied

  • Lung Cancer Stage IV

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Consecutive, treatment-naïve, patients with clinical and radiological suspicion of advanced lung cancer referred for the initial diagnosis/staging/molecular profiling.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Suspicion of lung cancer based on imaging (CT and/or PET/CT)
  • Indication to a for diagnosis, staging and/or molecular profiling

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide a written
  • performance status (>3) which makes a tissue diagnosis unfeasible
  • ASA 4 status
  • TNM Stage I-III
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • OtherAdvanced lung cancer patients' group

    Evaluation of the demographic, clinical, histological and molecular characteristics of advanced lung cancer at the time of Diagnosis

06

What researchers measure

Primary outcomes

  1. Distribution of histologic subtypes

    The investigators will assess the prevalence of histologic subtypes in patients with advanced lung cancer

    Time frame: 24 months

Secondary outcomes

  1. Distribution of histologic subtypes according to clinical and radiological characteristics

    The investigators will assess the prevalence of different histologic subtypes according to clinical and imaging characteristics

    Time frame: 24 months

  2. Molecular profiling

    Prevalence of individual molecular markers in patients with advanced non-squamous non-small cell lung cancer histology

    Time frame: 24 months

  3. Time to diagnosis

    Time lag between onset of symptoms (if any) and invasive testing

    Time frame: 24 months

07

Study locations

1 of 3 sites recruiting
  • Interventional Pulmonology Division - Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, Italy
    Recruiting
  • Istituto Nazionale Tumori Regina Elena
    Roma, Italy
    Not yet recruiting
    • Federico Cappuzzo, MD · Contact
  • Medical Oncology Division - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Italy
    Not yet recruiting
    • Emilio Bria · Contact
08

References and documents

Individual participant data

Plan to share: Undecided — The investigators will decide how to share the data at the end of the study upon reasonable request to be addressed to the principal investigator.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 35 months after the start.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's planned 35 months is below that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion May 2026 → Oct 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 10, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Oct 31, 2026was May 2026
CompletionEst.
Dec 31, 2026was Aug 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→Oct 31, 2026
Oct 27, 2026
Study completion
Aug 31, 2026→Dec 31, 2026
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion May 31, 2026→Oct 31, 2026
    Study completion Aug 31, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06076005
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Nov 1, 2023
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 27, 2026

Study contacts

Rocco Trisolini, MD
Contact
rocco.trisolini@policlinicogemelli.it
0630154163
Rocco Trisolini
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion